EP1929291A2 - Östrioltherapie für autoimmun- und neurodegenerative krankheiten und erkrankungen - Google Patents

Östrioltherapie für autoimmun- und neurodegenerative krankheiten und erkrankungen

Info

Publication number
EP1929291A2
EP1929291A2 EP06815626A EP06815626A EP1929291A2 EP 1929291 A2 EP1929291 A2 EP 1929291A2 EP 06815626 A EP06815626 A EP 06815626A EP 06815626 A EP06815626 A EP 06815626A EP 1929291 A2 EP1929291 A2 EP 1929291A2
Authority
EP
European Patent Office
Prior art keywords
treatment
mice
eae
disease
estriol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP06815626A
Other languages
English (en)
French (fr)
Other versions
EP1929291A4 (de
Inventor
Rhonda R. Voskuhl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Priority to EP13005320.0A priority Critical patent/EP2698167A3/de
Priority to EP16000349.7A priority patent/EP3045177A1/de
Publication of EP1929291A2 publication Critical patent/EP1929291A2/de
Publication of EP1929291A4 publication Critical patent/EP1929291A4/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP06815626A 2005-09-26 2006-09-26 Östrioltherapie für autoimmun- und neurodegenerative krankheiten und erkrankungen Ceased EP1929291A4 (de)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP13005320.0A EP2698167A3 (de) 2005-09-26 2006-09-26 Darreichungsform enthaltend Estriol und Glatiramerazetat (Polymer-1) zur Behandlung von Multipler Sklerose
EP16000349.7A EP3045177A1 (de) 2005-09-26 2006-09-26 Östrioltherapie für autoimmun- und neurodegenerative krankheiten und erkrankungen

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72097205P 2005-09-26 2005-09-26
US83352706P 2006-07-26 2006-07-26
PCT/US2006/037752 WO2007038636A2 (en) 2005-09-26 2006-09-26 Estriol therapy for autoimmune and neurodegenerataive diseases and disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP16000349.7A Division EP3045177A1 (de) 2005-09-26 2006-09-26 Östrioltherapie für autoimmun- und neurodegenerative krankheiten und erkrankungen
EP13005320.0A Division EP2698167A3 (de) 2005-09-26 2006-09-26 Darreichungsform enthaltend Estriol und Glatiramerazetat (Polymer-1) zur Behandlung von Multipler Sklerose

Publications (2)

Publication Number Publication Date
EP1929291A2 true EP1929291A2 (de) 2008-06-11
EP1929291A4 EP1929291A4 (de) 2010-12-22

Family

ID=37900442

Family Applications (3)

Application Number Title Priority Date Filing Date
EP06815626A Ceased EP1929291A4 (de) 2005-09-26 2006-09-26 Östrioltherapie für autoimmun- und neurodegenerative krankheiten und erkrankungen
EP16000349.7A Withdrawn EP3045177A1 (de) 2005-09-26 2006-09-26 Östrioltherapie für autoimmun- und neurodegenerative krankheiten und erkrankungen
EP13005320.0A Withdrawn EP2698167A3 (de) 2005-09-26 2006-09-26 Darreichungsform enthaltend Estriol und Glatiramerazetat (Polymer-1) zur Behandlung von Multipler Sklerose

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP16000349.7A Withdrawn EP3045177A1 (de) 2005-09-26 2006-09-26 Östrioltherapie für autoimmun- und neurodegenerative krankheiten und erkrankungen
EP13005320.0A Withdrawn EP2698167A3 (de) 2005-09-26 2006-09-26 Darreichungsform enthaltend Estriol und Glatiramerazetat (Polymer-1) zur Behandlung von Multipler Sklerose

Country Status (5)

Country Link
EP (3) EP1929291A4 (de)
JP (1) JP2009510084A (de)
AU (1) AU2006294662A1 (de)
CA (1) CA2623839C (de)
WO (1) WO2007038636A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130203722A1 (en) 2006-09-26 2013-08-08 Rhonda R. Voskuhl Estriol therapy for autoimmune and neurodegenerative disease and disorders
US6936599B2 (en) 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
US20120328566A9 (en) * 2001-04-25 2012-12-27 Rhonda R Voskuhl Estrogen receptor ligand treatment for neurodegenerative diseases
AU2006294826A1 (en) * 2005-09-26 2007-04-05 The Regents Of The University Of California Estriol therapy for autoimmune and neurodegenerative diseases and disorders
EP2164498A4 (de) * 2007-06-04 2010-09-08 Univ California Schwangerschaftshormonkombination zur behandlung von autoimmunkrankheiten
JP2010533656A (ja) * 2007-07-20 2010-10-28 ステム セル セラピューティクス コーポレイション プロラクチン及び免疫調節剤による、神経炎症若しくは脱髄障害の治療又は寛解
EP2200994B1 (de) 2007-10-26 2014-01-22 Acadia Pharmaceuticals Inc. Kondensierte verbindungen mit wirkung als östrogen-rezeptoren
HUP0800414A2 (en) * 2008-07-04 2010-10-28 Pecsi Tudomanyegyetem Pharmaceutical combination
CA2830519A1 (en) * 2011-03-22 2012-09-27 The Population Council, Inc. Myelin regeneration with androgens
EP2653163A1 (de) * 2012-04-19 2013-10-23 Université de Liège Östrogenverbindungen zur Verwendung bei der Behandlung von neurologischen Störungen
US9808470B2 (en) 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
EP3137087B1 (de) 2014-04-28 2023-09-06 The Regents of the University of California Östrogenkombination zur behandlung von multipler sklerose
US10369158B2 (en) 2014-04-28 2019-08-06 The Regents Of The University Of California Pharmaceutical packaging for estriol therapy
US20170160174A1 (en) * 2014-06-27 2017-06-08 National University Corporation Nagoya University Embedding medium for specimen preparation, method for preparing curable base material nonpenetrating specimen, method for preparing curable base material penetrating specimen, curable base material nonpenetrating specimen, thin slice performance improver for frozen embedding medium, and frozen embedding medium
US10821117B2 (en) 2014-09-02 2020-11-03 The Regents Of The University Of California Estrogen therapy for brain gray matter atrophy and associated disability
EP3189026B1 (de) * 2014-09-02 2020-07-22 The Regents of The University of California Östrogenrezeptorligand-behandlung für neurodegenerative erkrankungen
CA2962921A1 (en) 2014-09-29 2016-04-07 The Regents Of The University Of California Compositions and methods for maintaining cognitive function
EP3277285A4 (de) 2015-03-30 2018-12-19 The Regents of the University of California Verfahren zur überwachung einer estrioltherapie
AU2017322332A1 (en) * 2016-09-12 2019-04-04 Steven Hoffman Compositions for treating dementia
WO2018093765A1 (en) * 2016-11-15 2018-05-24 Regents Of The University Of California Methods and apparatuses for improving peripheral nerve function
BR112020022323A2 (pt) 2018-05-02 2021-02-23 Pantarhei Oncology B.V. componente estriol para uso no tratamento de câncer de mama avançado positivo para receptor de estrogênio, unidade de dosagem oral e kit de partes
TW202124418A (zh) * 2019-12-20 2021-07-01 比利時商埃斯特拉有限責任公司 壞死性凋亡調節劑、篩選方法及醫藥組成物
CN113243332B (zh) * 2020-02-07 2023-07-28 上海市东方医院（同济大学附属东方医院） 一种广泛脑区神经元树突发育障碍动物模型的制备与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US20010016325A1 (en) * 1999-12-01 2001-08-23 Mobley William C. Activation of novel estrogen receptor supports and neuronal viability and function

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9502921D0 (sv) 1995-08-23 1995-08-23 Astra Ab New compounds
US6734211B1 (en) * 1999-07-09 2004-05-11 Oregon Health & Sciences University Compositions and methods for promoting nerve regeneration
AR027878A1 (es) * 1999-11-05 2003-04-16 Wyeth Corp Metodos para identificar y utilizar compuestos inhibidores de amiloides
AU2002237126A1 (en) * 2001-03-02 2002-09-19 Stem Cell Therapeutics Inc. Use of ovarian hormone for increasing neural stem cell number
US6936599B2 (en) * 2001-04-25 2005-08-30 The Regents Of The University Of California Estriol therapy for multiple sclerosis and other autoimmune diseases
US20050209208A1 (en) * 2001-04-25 2005-09-22 The Regents Of The University Of California Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders
JP4801868B2 (ja) * 2002-02-25 2011-10-26 晃史 山口 全身性エリテマトーデス発病抑制薬
EP1358881A1 (de) * 2002-04-30 2003-11-05 Schering Aktiengesellschaft Verwendung von biogenen Estrioldiester-Prodrugs zur Behandlung von Autoimmunkrankheiten
AU2006294826A1 (en) * 2005-09-26 2007-04-05 The Regents Of The University Of California Estriol therapy for autoimmune and neurodegenerative diseases and disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US20010016325A1 (en) * 1999-12-01 2001-08-23 Mobley William C. Activation of novel estrogen receptor supports and neuronal viability and function

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BIEWENGA E ET AL: "Estradiol and raloxifene protect cultured SN4741 neurons against oxidative stress" NEUROSCIENCE LETTERS, vol. 373, no. 3, 20 January 2005 (2005-01-20), pages 179-183, XP004690113 LIMERICK, IE ISSN: 0304-3940 DOI: 10.1016/J.NEULET.2004.09.067 *
KUMAR D M ET AL: "Role of nonfeminizing estrogen analogues in neuroprotection of rat retinal ganglion cells against glutamate-induced cytotoxicity" FREE RADICAL BIOLOGY AND MEDICINE, vol. 38, no. 9, 1 May 2005 (2005-05-01), pages 1152-1163, XP025352119 ELSEVIER SCIENCE, US ISSN: 0891-5849 [retrieved on 2005-05-01] *
OFFNER, HALINA: "Neuroimmunoprotective effects of estrogen and derivatives in experimental autoimmune encephalomyelitis: Therapeutic implications for multiple sclerosis" JOURNAL OF NEUROSCIENCE RESEARCH, vol. 78, no. 5, 28 October 2004 (2004-10-28), pages 603-624, XP002605593 ISSN: 0360-4012 *
PERRELLA, JOEL ET AL: "Protection of cortical cells by equine estrogens against glutamate-induced excitotoxicity is mediated through a calcium independent mechanism" BMC NEUROSCIENCE, vol. 6, 34, 10 May 2005 (2005-05-10), page 17PP, XP002605592 ISSN: 1471-2202 *
SAMANTHA S SOLDAN ET AL: "Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol" JOURNAL OF IMMUNOLOGY, vol. 171, no. 11, 1 December 2003 (2003-12-01), pages 6267-6268, XP008126547 AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US ISSN: 0022-1767 *
See also references of WO2007038636A2 *
WEN, YI ET AL: "Transient Cerebral Ischemia Induces Aberrant Neuronal Cell Cycle Re-entry and Alzheimer 's Disease-like Tauopathy in Female Rats" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 21, 24 February 2004 (2004-02-24), pages 22684-22692, XP002605887 ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2007038636A2 (en) 2007-04-05
AU2006294662A1 (en) 2007-04-05
CA2623839C (en) 2013-12-17
WO2007038636A3 (en) 2007-12-27
EP2698167A3 (de) 2014-03-05
JP2009510084A (ja) 2009-03-12
EP3045177A1 (de) 2016-07-20
EP2698167A2 (de) 2014-02-19
EP1929291A4 (de) 2010-12-22
CA2623839A1 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
CA2623839C (en) Estriol therapy for autoimmune and neurodegenerataive diseases and disorders
US20090131385A1 (en) Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders
US10610535B2 (en) Diarylpropionitrile therapy for treatment of multiple sclerosis
US8372826B2 (en) Estriol therapy for multiple sclerosis and other autoimmune diseases
EP1928468A2 (de) Östriol-therapie gegen autoimmunkrankheiten und neurodegenerative erkrankungen und störungen
US9452175B2 (en) Pregnancy hormone combination for treatment of autoimmune diseases
US20120328566A9 (en) Estrogen receptor ligand treatment for neurodegenerative diseases
WO2006053172A2 (en) The use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune diseases
Ahrendt et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel
US20210137943A1 (en) Estrogen combination for treatment of multiple sclerosis
Gold et al. Estrogen treatment in multiple sclerosis
US20110256096A1 (en) Estrogen receptor ligand and/or interferon beta treatment for neurodegenerative diseases
US20090297477A1 (en) Estriol Therapy for Autoimmune and Neurodegenerative Disease and Disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080331

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20101022BHEP

Ipc: A61K 31/568 20060101ALI20101022BHEP

Ipc: A61K 31/566 20060101ALI20101022BHEP

Ipc: A61K 31/565 20060101ALI20101022BHEP

Ipc: G01N 33/00 20060101AFI20080408BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20101118

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130122

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20151228